EGFR methylation and outcome of patients with advanced colorectal cancer treated with cetuximab

E-ISSN： 1792-1082|9|3|1432-1438

ISSN： 1792-1074

Source： Oncology Letters, Vol.9, Iss.3, 2015-01, pp. : 1432-1438

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Addition of sunitinib to cetuximab and irinotecan in patients with heavily pre-treated advanced colorectal cancer

By Qvortrup Camilla Jensen Benny Vittrup Jorgensen Trine Lembrecht Nielsen Dorte Bjerregaard Jon Kroll Pfeiffer Per

Acta Oncologica, Vol. 49, Iss. 6, 2010-08 ,pp. : 833-836

Informa Healthcare

Access to resources Recommend Favorite

Serum matrilysin correlates with poor survival independently of KRAS and BRAF status in refractory advanced colorectal cancer patients treated with irinotecan plus cetuximab

By Garcia-Albeniz Xabier

Tumor Biology, Vol. 32, Iss. 2, 2011-04 ,pp. : 417-424

Springer Publishing Company

Access to resources Recommend Favorite

Incidence and risk of hypomagnesemia in advanced cancer patients treated with cetuximab: A metaanalysis

Oncology Letters, Vol. 5, Iss. 6, 2013-01 ,pp. : 1915-1920

Spandidos Publications

Access to resources Recommend Favorite

Should Patients with Advanced Colorectal Cancer be Treated with Chemotherapy?

By Blijham G.H. Labianca R. Bleiberg H.

European Journal of Cancer, Vol. 33, Iss. 6, 1997-05 ,pp. : 815-824

Elsevier

Access to resources Recommend Favorite

Correlation of EGFR, IDH1 and PTEN status with the outcome of patients with recurrent glioblastoma treated in a phase II clinical trial with the EGFR-blocking monoclonal antibody cetuximab

International Journal of Oncology, Vol. 41, Iss. 3, 2012-01 ,pp. : 1029-1035

Spandidos Publications

Access to resources Recommend Favorite